Skip to content
Home » Lyme disease vaccine shows excellent clinical trial results

Lyme disease vaccine shows excellent clinical trial results


Pfizer and Valneva have announced positive clinical trial results from their investigational 6-valent OspA-based Lyme disease vaccine candidate LB6V, formerly known as VLA15. Preliminary results from the clinical trial were available a few months ago, but Pfizer and Valneva have updated their data.

Lyme disease remains one of the most common vector-borne infectious diseases in the Northern Hemisphere, and its prevalence continues to increase. In the US, approximately 476,000 cases are diagnosed and treated each year, while in Europe, more than 130,000 cases are reported annually. So, getting a Lyme disease vaccine has been a goal for a long time.

This article will examine what Lyme disease is and the results from the phase three clinical trial for the vaccine.

lyme vaccine efficacy

What is Lyme disease?

Lyme disease is an infectious disease caused by at least three species of bacteria belonging to the genus Borrelia. Of the three species, Borrelia burgdorferi is the main cause of Lyme disease in North America, whereas Borrelia afzelii and Borrelia garinii are more prevalent in Europe. The disease was named after the towns of Lyme and Old Lyme, Connecticut, where several cases were initially identified in 1975.

Borrelia is transmitted to humans when humans are bitten by infected ticks, which belong to a few species of the genus Ixodes, called “hard-bodied” ticks. Although deer ticks, Ixodes scapularis, Ixodes pacificus, and Ixodes ricinus, are commonly considered vectors for Borrelia infection. Some other species in the Ixodes genus can transmit the disease. Lyme disease is the most common tick-borne disease in the United States.

There are several initial symptoms of Lyme disease – fever, headache, fatigue, depression, and a circular skin rash called erythema migrans (EM). If the Borrelia infection is not treated promptly, other symptoms may appear, including joint, heart, and central nervous system involvement.

There is generally only one known treatment for a Borrelia infection – antibiotics, which may include doxycycline, amoxicillin, and cefuroxime. Generally, the symptoms resolve after antibiotic treatment.

While the true incidence of Lyme disease is unknown, it is estimated to affect approximately 476,000 people annually in the USA and 130,000 people in Europe.

The only FDA-approved Lyme disease vaccine, LYMErix, was developed by SmithKlineBeecham (known now as GlaxoSmithKline) and introduced to the US market in 1998. It was given in a three-dose series. The vaccine worked uniquely – it stimulated antibodies that attacked B. burgdorferi bacteria in the tick’s gut as the tick was feeding on the human host. Thus, the bacteria were attacked before they could enter the human body. It was about 78% effective in preventing Lyme disease after all three doses were given. Better yet, the vaccine was also shown to be nearly 100% effective at preventing asymptomatic Lyme disease, in which an individual would get the disease and develop antibodies against it but never develop symptoms.

In 2002, SmithKlineBeecham withdrew the vaccine from the market, and Pasteur Mérieux Connaught, which also had a Lyme disease vaccine, decided to withdraw its application to the FDA, despite showing safety and effectiveness in a Phase III clinical trial.

So what happened to these vaccines? I wrote previously about the demise of the human Lyme disease vaccine, so I’ll summarize it here.

LYMErix was a huge success in areas where Lyme disease was endemic. The vaccine was safe and effective. Between December 28, 1998, and July 31, 2000, nearly 1.5 million doses of the vaccine had been given to patients in high-risk areas of the USA. During that same time, over 905 reports were made to the Vaccine Adverse Event Reporting System  (VAERS) about adverse events after the administration of the Lyme disease vaccine.

Predictably, large lawsuits were filed against SmithKlineBeecham (because LYMErix was outside of the Vaccine Injury Compensation Plan coverage), and anti-vaxxers did their usual campaign against the vaccine. And, as I wrote above, the vaccine was withdrawn from the market.

On the other hand, there are three Lyme disease vaccines for dogs –LymeVax, from Fort Dodge Laboratories; Galaxy Lyme, from Intervet-Schering-Plough; and Canine Recombinant Lyme, from Merial. Each works in a slightly different manner — Merial’s vaccine is similar to the human version, where the antibodies attack the bacteria in the tick’s gut. The vaccine isn’t recommended for all dogs, just those in areas with a risk of Lyme disease.

So your dogs are better protected against Lyme disease than their humans.

vials with specimens
Photo by Artem Podrez on Pexels.com

Lyme disease vaccine Phase 3 clinical trial results

The phase 3 clinical trial for the LB6V vaccine candidate was a multicenter, placebo-controlled, randomized, observer-blinded trial conducted at sites in areas of high Lyme disease incidence across the USA, Canada, and Europe. Trial participants aged 5 years and older were randomized 1:1 into two trial groups and received four doses of either LB6V or a saline placebo – one dose administered at months 0, 2, 5-9, followed by a fourth dose one year later, shortly before the start of the following Lyme disease season (season 2).

The vaccine targets the outer surface protein A (OspA), each representing a separate serotype, of Borrelia burgdorferi. This vaccine protects against six different serotypes that are epidemiologically relevant in North America and Europe.

After immunization, the body produces antibodies against all OspA serotypes. When a tick feeds on the blood, these antibodies enter the tick’s gut and bind to Borrelia bacteria, blocking transmission to the human host. This vector-targeted approach differs from most vaccines, which primarily stimulate immune responses within the human body against the pathogen.

Here are the key results from the study:

  • Efficacy of 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease cases compared to the placebo arm.
  • Efficacy of 74.8% from 1-day post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease cases compared to the placebo arm.
  • The vaccine candidate showed favorable tolerability in the clinical trial, and no safety signals were found at the time of analysis.

Summary

This is excellent news about the Lyme disease vaccine candidate from Pfizer and Valneva. And with these results, they should receive approval in the US and Europe to market the vaccine. Unfortunately, with the anti-vaccine regime in Washington, I worry that it might not get approved.

Lyme disease is widespread and dangerous, so preventing it should be the goal of any public health official. I should not worry that it might not get approval, but after watching what’s going on with vaccines recently, my worries are probably with merit.

I know some of you will wonder how long it might take for approval. It’s hard to say with the current vaccine environment, but it should be around a year from now.

Finally, this clinical trial used a saline placebo for the control group. Maybe that will be enough for the anti-vaccine crowd that seems to be controlling our vaccine policy.

Help the Skeptical Raptor keep writing about vaccines

There are four ways you can help contribute to keeping this website running at full speed:

  1. GoFundMe.
  2. Subscribing via Patreon.
  3. Buying your favorite stuff on Amazon
  4. Sharing this article on Social Media.

Don’t miss each new article!

We don’t spam! Read our privacy policy for more info.

Liked it? Take a second to support Michael Simpson on Patreon!
Become a patron at Patreon!


Discover more from Skeptical Raptor

Subscribe to get the latest posts sent to your email.

Discover more from Skeptical Raptor

Subscribe now to keep reading and get access to the full archive.

Continue reading